Dietary phytosterols reduce probucol-induced atherogenesis in apo E-KO mice.
We have previously shown strong pro-atherogenic effects of probucol in apolipoprotein E-knockout (apo E-KO) mice. The aims of the present study were to investigate whether (a) dietary phytosterols reduce probucol-induced atherogenesis and (b) beneficial interactions exist between these agents. Male apo E-KO mice fed with an atherogenic diet supplemented with phytosterols or probucol or their combination for 14 weeks. Single therapy with either phytosterols or probucol resulted in a 25% reduction in plasma total cholesterol (TC) concentrations as compared to the control group. The effects of the combination therapy were more profound (60% reduction). While phytosterols reduced atherogenesis by 60%, probucol caused an increase of 150% in atherogenesis. Addition of phytosterols to probucol substantially reduced pro-atherogenic effects of probucol. This was associated with improved high density lipoprotein (HDL) concentrations. The ratio of TC to HDL cholesterol was markedly reduced in the combination therapy group as compared to the probucol-treated group. A strong positive association between the ratio of TC to HDL cholesterol and the extent of atherosclerotic lesions was observed. The coronary arteries of the probucol-treated group showed various stages of atherogenesis from infiltration of monocytes into intima to complete occlusion of the vessel by atheromatous lesions. Such pathological findings were not observed in the combination therapy group. Approximately 40% of the mice in the probucol-treated group and 10% of the animals in the combination therapy group developed skin lesions. Further studies warrant the investigation of the underlying mechanisms of the observed beneficial interactions between dietary phytosterols and probucol.
Moghadasian
Mohammed H
MH
Departments of Human Nutritional Sciences and Pathology, The University of Manitoba, Winnipeg, Man., Canada R2H 2A6. mmoghadsian@sbrc.ca
D000818:Animals; D000924:Anticholesteremic Agents / Q000037:antagonists & inhibitors* / Q000633:toxicity; D001057:Apolipoproteins E / Q000235:genetics; D050197:Atherosclerosis / Q000139:chemically induced / Q000178:diet therapy* / Q000473:pathology; D001835:Body Weight; D002784:Cholesterol / Q000097:blood; D008076:Cholesterol, HDL / Q000097:blood; D004032:Diet; D004336:Drug Antagonism; D008297:Male; D051379:Mice; D018345:Mice, Knockout; D010840:Phytosterols / Q000008:administration & dosage*; D011341:Probucol / Q000037:antagonists & inhibitors* / Q000633:toxicity
D000924:Anticholesteremic Agents; D001057:Apolipoproteins E; D008076:Cholesterol, HDL; D010840:Phytosterols; D002784:Cholesterol; D011341:Probucol